Cargando…
CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults
Atopic dermatitis (AD) is a condition frequently encountered in medical practices across the country. Arming ourselves with appropriate and safe treatment modalities to provide relief for this chronic and relapsing inflammatory condition is of utmost importance to our patients and their families. Ut...
Autores principales: | Segal, Audrey O, Ellis, Anne K, Kim, Harold L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707742/ https://www.ncbi.nlm.nih.gov/pubmed/23837743 http://dx.doi.org/10.1186/1710-1492-9-24 |
Ejemplares similares
-
CSACI position statement: epinephrine auto-injectors and children < 15 kg
por: Halbrich, Michelle, et al.
Publicado: (2015) -
CSACI position statement: prescribing sublingual immunotherapy tablets for aeroallergens
por: Quirt, J., et al.
Publicado: (2018) -
Topical Calcineurin Inhibitors for Atopic Dermatitis: Review and Treatment Recommendations
por: Carr, Warner W.
Publicado: (2013) -
CSACI Position statement on the testing of food-specific IgG
por: Carr, Stuart, et al.
Publicado: (2012) -
CSACI position statement: transition recommendations on existing epinephrine autoinjectors
por: Li, Lucy Dong Xuan, et al.
Publicado: (2021)